We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Tissue of Origin Test Determines Tumor's Origin

By Biotechdaily staff writers
Posted on 13 Nov 2007
A new, genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin. More...
The test uses microarray technology and proprietary analytics designed to measure the expression of more than 1,600 genes and compare a tumor's genetic "signature” against those of 15 known tissue types.

There are an estimated 200,000 cancer patients each year in the United States who may benefit from additional diagnostic information to determine the tissue of origin for their cancer. U.S. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

Pathwork Diagnostics (Sunnyvale, CA, USA), a genomics-based diagnostics company focused on oncology, reported that Virginia Commonwealth University (VCU) School of Medicine (Richmond VA, USA) has initiated an investigational study of the Tissue of Origin Test. The company's first test--the Pathwork Tissue of Origin Test--is designed to be an aid in the diagnosis of the tissue of origin in patients with undifferentiated or poorly differentiated tumors or metastases. The company's tests consist of Pathwork Diagnostics' analytics and a companion Pathchip microarray, which runs on the Affymetrix (Santa Clara, CA, USA) instrument system

"Patient cases in which a tumor cannot be readily identified are a significant problem,” said Catherine Dumur, Ph.D., director of molecular morphology genomics for the department of pathology, VCU. "Such cases are time-consuming for physicians and anxiety-producing for patients, and are a challenge to providing the most appropriate care for the patient. We are eager to see how this investigational new genomics-based test extends and complements traditional histopathological approaches.”

The Tissue of Origin Test was the focus of two workshops and two poster presentations at the 12th annual meeting of the Association for Molecular Pathology held on November 7-10, 2007, in Los Angeles (CA, USA).


Related Links:
Pathwork Diagnostics
Virginia Commonwealth University School of Medicine
Affymetrix

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.